3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Genitourinary
1
Breast
1
Conditions
Thrombosis
1
Thromboembolism
1
Prostatic Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Inflammation
1
Immune System Diseases
1
Colonic Neoplasms
1
Cardiovascular Diseases
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
16
Cyclophosphamide
9
Nivolumab
7
atezolizumab
6
fludarabine
5
Specimen Handling
5
Magnetic Resonance Spectroscopy
5
cabozantinib
4
Trastuzumab
4
budigalimab
3
Ipilimumab
3
Interleukin-2
3
Cisplatin
3
Capecitabine
3
Albumin-Bound Paclitaxel
3
spartalizumab
2
sargramostim
2
poly ICLC
2
palbociclib
2
lenvatinib
2
epacadostat
2
durvalumab
2
avelumab
2
X-Rays
2
Sunitinib
2
Paclitaxel
2
Irinotecan
2
Interleukin-12
2
Immunoglobulin G
2
Gemcitabine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Hepatocellular
×
Rivaroxaban
×
Breast
×
Clear all
NCT06065592
2023-10-06
CAT_PB
Lebanese University
Phase 1
Unknown
500 enrolled